299 related articles for article (PubMed ID: 15970901)
1. Acquired von Willebrand disease: management of labor and delivery with intravenous dexamethasone, continuous factor concentrate, and immunoglobulin infusion.
Lipkind HS; Kurtis JD; Powrie R; Carpenter MW
Am J Obstet Gynecol; 2005 Jun; 192(6):2067-70. PubMed ID: 15970901
[TBL] [Abstract][Full Text] [Related]
2. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
3. Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.
Eikenboom JC; Tjernberg P; Van Marion V; Heering KJ
Am J Hematol; 2007 Jan; 82(1):55-8. PubMed ID: 16986130
[TBL] [Abstract][Full Text] [Related]
4. [Acquired von Willebrand syndrome].
de Lange DW; Fijnheer R; Wittebol S
Ned Tijdschr Geneeskd; 2003 Sep; 147(37):1808-11. PubMed ID: 14526622
[TBL] [Abstract][Full Text] [Related]
5. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
Güth U; Tsakiris DA; Reber A; Holzgreve W; Hösli I
Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion of von Willebrand factor and factor VIII after elective heart surgery in a 12-year-old girl with von Willebrand disease type 3.
Kühne T; Imbach P; Marbet GA; Caliezi C; Devay J
Pediatr Hematol Oncol; 1999; 16(6):551-6. PubMed ID: 10599096
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
Federici AB
Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
[TBL] [Abstract][Full Text] [Related]
8. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
Nichols WL; Hultin MB; James AH; Manco-Johnson MJ; Montgomery RR; Ortel TL; Rick ME; Sadler JE; Weinstein M; Yawn BP
Haemophilia; 2008 Mar; 14(2):171-232. PubMed ID: 18315614
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of acquired von Willebrand syndrome.
Federici AB; Mannucci PM
Clin Adv Hematol Oncol; 2003 Mar; 1(3):169-75. PubMed ID: 16224398
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
11. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome.
Macik BG; Gabriel DA; White GC; High K; Roberts H
Arch Pathol Lab Med; 1988 Feb; 112(2):143-6. PubMed ID: 2447856
[TBL] [Abstract][Full Text] [Related]
12. Acquired von Willebrand syndrome: features and management.
Mohri H
Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
[TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease.
Patel SB; Rodgers GM
Haemophilia; 2014 Nov; 20(6):e411-4. PubMed ID: 25333342
[No Abstract] [Full Text] [Related]
15. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
17. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Sucker C; Michiels JJ; Zotz RB
Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
Rivard GE; Aledort L;
Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease.
Smith MP; Rice KM; Bromidge ES; Lawn M; Beresford-Webb R; Spence K; Khair K; Hann I; Savidge GF
Blood Coagul Fibrinolysis; 1997 Jan; 8(1):6-12. PubMed ID: 9105631
[TBL] [Abstract][Full Text] [Related]
20. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease.
van Genderen PJ; Terpstra W; Michiels JJ; Kapteijn L; van Vliet HH
Thromb Haemost; 1995 May; 73(5):891-2. PubMed ID: 7482422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
